Avanti Biosciences Inc
Biotech · Private
ABI-171, a small-molecule DYRK1A/1B inhibitor therapeutic for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
avantibiosciences.com →- Grants
- $3.7M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 0 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of DYRK1A allosteric modulator for the treatment of Alzheimer’s Disease | $582,601 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of novel prodrugs targeting Glutamate Dehydrogenase (GDH) for the treatment of congenital hyperinsulinemia disorder including Hyperinsulinemia-Hyperammonemia Syndrome (HHS) and SCHAD-HI. | $298,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of novel prodrugs targeting Glutamate Dehydrogenase (GDH) for the treatment of congenital hyperinsulinemia disorder including Hyperinsulinemia-Hyperammonemia Syndrome (HHS) and SCHAD-HI. | $298,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DYRK1A allosteric modulator for the treatment of Alzheimer’s Disease | $971,320 | |
| Federal grant | Department of Health and Human Services · Phase I · DYRK1A inhibitors as therapeutic approach to Tau hyper-phosphorylation for treatment of Alzheimer disease and other CNS disorders | $449,436 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DYRK1A allosteric modulator for the treatment of Alzheimer’s Disease | $350,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease | $375,862 | |
| Federal grant | Department of Health and Human Services · Phase I · Use Of DYRK1A/B Kinase Inhibitors For The Treatment Of Liver Diseases | $349,235 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2159 | NOVAZOI THERANOSTICS | — | — |
| 2160 | PSYENCE BIOMEDICAL LTD. | — | $2.0M |
| 2161 | MITORAINBOW THERAPEUTICS, INC. | — | — |
| 2162 | Avanti Biosciences Inc | — | — |
| 2163 | VAXCYTE, INC. | — | — |
| 2164 | Arctus Biosciences | — | — |
| 2165 | NEMALIFE INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Antioxidant And Anti-inflammatory Therapeuticsapplication
- Methods Of Treating Cognitive And Behavioral Impairment In Down Syndrome And Alzheimers Disease Patientsapplication
- Methods Of Treating Cognitive And Behavioral Impairment In Down Syndrome And Alzheimers Disease Patientsapplication
- Small Molecule Inhibitors of DYRK1Aapplication
- Methods For Treating Fibrotic Diseaseapplication
- Methods And Formulations For Intranasal Administrationapplication
- Methods and Formulations for Intranasal Administrationapplication
- Small Molecule Inhibitors of DYRK1Aapplication
- Methods For Treating Fibrotic Diseaseapplication
- Compositions And Methods For Antioxidant And Anti-inflammatory Therapeuticsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.